To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00114313
Entity page: /trial/NCT03006172 ↗
Edges: 9

Neighbours: 2 cancers7 drugs
Drawn: 9 of 9 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer condition of …CONDITION_OFderived2 of 2
← condition of	Malignant Breast Neoplasm registry condition “Breast Cancer” mapped CURATED_EXACT	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Solid Neoplasm registry condition “Solid Tumor” mapped CURATED_BROADER

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Fulvestrantsmall molecule registry intervention “Fulvestrant” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Inavolisibsmall molecule registry intervention “Inavolisib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Letrozolesmall molecule registry intervention “Letrozole” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Metforminsmall molecule registry intervention “Metformin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Palbociclibsmall molecule registry intervention “Palbociclib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pertuzumabmonoclonal antibody registry intervention “Pertuzumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Trastuzumabmonoclonal antibody registry intervention “Trastuzumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Fulvestrantsmall molecule

registry intervention “Fulvestrant” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Inavolisibsmall molecule

registry intervention “Inavolisib” (DRUG) mapped ALIAS

—